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The HIV envelope glycoprotein (Env) is densely
covered with self-glycans that should help shield it
from recognition by the human immune system.
Here, we examine how a particularly potent family
of broadly neutralizing antibodies (Abs) has evolved
common and distinct structural features to counter
the glycan shield and interact with both glycan and
protein components of HIV Env. The inferred germ-
line antibody already harbors potential binding
pockets for a glycan and a short protein segment. Af-
finity maturation then leads to divergent evolutionary
branches that either focus on a single glycan and
protein segment (e.g., Ab PGT124) or engage multi-
ple glycans (e.g., Abs PGT121–123). Furthermore,
other surrounding glycans are avoided by selecting
an appropriate initial antibody shape that prevents
steric hindrance. Suchmolecular recognition lessons
are important for engineering proteins that can re-
cognize or accommodate glycans.INTRODUCTION
The HIV-1 envelope glycoprotein (Env) trimer is the sole target of
the neutralizing antibody response and the primary platform for
vaccine design. However, variable loops on gp120 mediate
antibody escape, and extensive N-linked glycosylation shields
much of the Env protein surface from immune recognition. Addi-
tionally, many antibodies against monomeric gp120 bind without
measurable glycan involvement or show enhanced bindingfollowing deglycosylation (Binley et al., 1998; Koch et al., 2003;
Ma et al., 2011). Notwithstanding, a number of potent broadly
neutralizing antibodies (bnAbs) have recently been discovered
that bind to a heavily glycosylated region around the base of
the V3 loop that we have termed a supersite of vulnerability
(Kong et al., 2013). These bnAbs include antibody families from
different germline lineages such as PGT121–123/PGT133–
134/10-1074, PGT125–128/PGT130–131, and PGT135–137 (Ju-
lien et al., 2013c; Kong et al., 2013; Mouquet et al., 2012; Pejchal
et al., 2011;Walker et al., 2011). Crystal structuresof PGT128and
PGT135 in complex with gp120 outer domain and with gp120
core, respectively, and PGT122 in complex with the soluble
cleaved BG505 SOSIP.664 gp140 trimer (SOSIP.664) (Julien
et al., 2013a, 2013b; Kong et al., 2013; Pejchal et al., 2011)
have enabled molecular characterization of their glycan-depen-
dent bnAb epitopes. Although these bnAbs are derived from
different germline lineages, they all interact with the Asn332
(N332) glycan that is highly conserved across the majority of
HIV-1 isolates. In addition, PGT128 binds the glycan at Asn301
(N301) and the base of the gp120 V3 loop, PGT135 interacts
with glycans at Asn386 (N386) and Asn392 (N392) and an exten-
sive b sheet motif on the gp120 outer domain, and PGT122 con-
tacts glycansatN301, Asn137 (N137), andAsn156 (N156), aswell
as protein components of the V1 and V3 loops. A family of trimer-
preferring antibodies, PG9/PG16, also recognizesN156 in V1 but
interactswith aglycan inV2, Asn160 (N160) at the trimer apex (Ju-
lien et al., 2013a; McLellan et al., 2011). A common feature of
these antibodies is interaction with multiple glycans and protein
components to achieve high affinity. Indeed, these same bnAbs
generally have low or undetectable affinity to single glycans
(McLellan et al., 2011; Mouquet et al., 2012). For carbohydrate-
binding lectins, highaffinities that are relevant in vivoare achieved
through interaction with multiple glycans (Dam et al., 2000). OnlyCell 159, 69–79, September 25, 2014 ª2014 Elsevier Inc. 69
Figure 1. Crystal Structure of PGT124 in
Complex with HIV-1 gp120 and CD4
(A) The ternary complex of PGT124 (purple and
brown for heavy and light chains, respectively) and
two-domain CD4 (gray) bound to gp120 (light blue)
are shown as a ribbon representation. PGT124
contacts the N332 glycan and the base of V3. The
glycan is represented in ball and stick with green
carbons, red oxygens, and blue nitrogens and
covered with its molecular surface.
(B) CDR H3, L1, L2, and L3 loops and the light-
chain FR3 make extensive contacts with both the
Man8 N332 glycan and V3 (in red) of gp120.
(C) The surface areas (A˚2) buried on the gp120
protein and N332 glycan by individual CDR loops
and framework regions on PGT124 are presented
on the lower right.
(D) Fitting of the PGT122-BG505 SOSIP.664
gp140 crystal structure into the PGT124:BG505
SOSIP EM reconstruction at 17.8 A˚ resolution.
The PGT122 fitting is excellent with a correlation
of 0.9, indicating that PGT122 and PGT124 share
a similar angle of approach for interaction with
Env (see also Figures S1 and S2 and Tables S1
and S6).one HIV-1 antibody, 2G12, has been able to attain high affinity
for glycans alone by using multivalency through domain swap-
ping of the variable heavy chain (VH) domains, whereby two
tightly linked Fabs then bind multiple glycans in the N332 high
mannose patch (Calarese et al., 2003). To achieve high-affinity
binding without multivalency, a combination of glycan and pro-
tein interactions would appear to be a more general solution.
PGT122 is a member of the PGT121 family of bnAbs, which are
among the most potent antibodies identified to date. Passively
administered PGT121 protects against mucosal SHIV (chimeric
simian HIV) challenge in macaques at serum concentrations
achievable by vaccination and causes a dramatic and sustained
lowering of viral load in established SHIV infection (Moldt et al.,
2012; Barouch et al., 2013). The crystal structure of BG505
SOSIP.664 with PGT122 revealed how an affinity-matured anti-
body from the PGT121 family recognizes gp120 in the context of
the Env trimer (Julien et al., 2013a). PGT124 is a newly discovered
bnAb from the same germline lineage as PGT121 but represents
an alternative branch in the antibody maturation process and is
89% identical in VH amino acid sequence to 10-1074 (Figure S1C
available online) (Mouquet et al., 2012; Sok et al., 2013, 2014).
Structural comparison of representatives from these two
different evolutionary branches therefore provides an opportu-
nity to investigate the evolution of high-affinity recognition of an
epitope involving glycans and protein surfaces. Molecular70 Cell 159, 69–79, September 25, 2014 ª2014 Elsevier Inc.details of the PGT124-gp120 interaction
were determined by X-ray crystallography
and EM, with additional functional and
biochemical insights from isothermal
titration calorimetry (ITC), next-generation
sequencing, virus neutralization, and
glycan arrays. Surprisingly, PGT124 en-
gages in a distinct mode of interactionwith the N332 supersite of vulnerability that involves a single
glycan, whereas PGT122 contacts multiple glycans.
RESULTS
Structural Characterization of PGT124 in Complex
with gp120 and CD4
To identify the PGT124 epitope, we cocrystallized PGT124 Fab
in complex with a gp120 core containing a mini-V3 loop (mV3)
(Pejchal et al., 2011). The JRCSF gp120mV3 core was produced
in a GnTI/ mutant cell line that yields Man5-9GlcNAc2 oligo-
mannose glycans (Chang et al., 2007; Reeves et al., 2002). The
complex was deglycosylated by Endoglycosidase H (EndoH)
to remove glycans not protected by PGT124 binding, and two-
domain soluble CD4 was added to facilitate crystallization. The
crystal structure was determined at 3.3 A˚ with four ternary com-
plexes in the asymmetric unit (Tables S1 and S6).
Themost prominent interaction of PGT124with gp120 is with a
single Man8GlcNAc2 glycan (Man8) linked to N332 and a small
protein segment at the V3 loop base (Figures 1A and 1B). Struc-
turally, both protein and glycan components make comparable
contributions to the PGT124 epitope, as the bnAb buries
428 A˚2 of gp120 polypeptide and 480 A˚2 of N332 Man8 glycan
(Figure 1C). Whereas the N332 glycan was protected from En-
doH deglycosylation by the antibody prior to crystallization,
Figure 2. Interaction between PGT124 and
the Base of the V3 Loop
(A) The interaction between PGT124 CDR loops
(purple ribbons) and the base of the V3 loop (red
ribbon). Red dots represent residues at the tip of the
mini-V3 loop that are not visible in the electron
density. The interaction with contacting residues is
displayed in ball-and-stick representation below.
Contacts between side chains of the 324GDIR327
motif on the V3 loop and the CDR loops of PGT124
are indicated with solid lines for van der Waals’ in-
teractions and dotted lines for hydrogen bonds.
(B) For comparison, the interaction between
PGT128 CDR loops (pale green) and the base of the
V3 (gray) (PDB 3TYG) for comparison with (A). The
PGT128 antibody-antigen interactions with the V3
base are all H bonds of the Fab main chain with V3
main chain.
(C) The V3 loop structures bound to PGT124 or
PGT128 are superimposed for comparison.
(D) The effect on the neutralization activity of
PGT124 and PGT128 by single and double muta-
tions of the V3 loop GDIR motif. Values are shown
as IC50 in mg/ml (see also Figures S3, S4, and S5).most other glycans appear to be cleaved, as indicated by elec-
tron density for only single N-acetylglucosamine (GlcNAc) moi-
eties at N262, N276, N295, N301, N339, N355, N386, N392,
N411, and N448. Thus, it is unlikely that the N301 glycan near
the base of V3 makes productive contacts with PGT124. How-
ever, additional electron density at N295 and N339 could be as-
signed to two core GlcNAcs (data not shown) in one of the four
copies in the asymmetric unit, suggesting partial protection
from cleavage by EndoH. Electron density for gp120 was mostly
unambiguous except for the mV3 tip, which is disordered. How-
ever, the V3 base is highly ordered as PGT124 makes its only
contacts with the gp120 polypeptide in this region (Figure 2A).
Superposition of the unliganded PGT124 structure at 2.5 A˚ (Ta-
ble S1) with its bound form gave an all-atom root mean square
deviation (rmsd) of 0.6 A˚, indicating nomajor changes in the anti-
body on gp120 binding (Figure S1A).
To characterize the PGT124 interaction in the context of the
SOSIP.664 Env trimer (Depetris et al., 2012; Sanders et al.,
2002), we derived negative-stain electron microscopy (EM) im-
ages at 17.8 A˚ resolution. Three Fabs are bound per trimer
with each oriented diagonally relative to the trimer axis (Fig-
ure S2A). The PGT122:SOSIP.664 crystal structure (PDB
ID:4NCO) fits extremely well into the PGT124:SOSIP.664 EM
reconstruction, indicating that both bnAbs approach Env at a
similar angle (Figure 1D).
Molecular Basis of PGT124 Recognition of gp120
Polypeptide
PGT124 recognizes the 324GDIR327 region at the V3 loop base.
As other N332-dependent antibodies, including PGT128, bind
this same sequence, this motif may be a common anchor point.
For PGT124, Ser30 and Ser93 in CDR L1 and L3, respectively,
interact with the gp120 Asp325 carboxylate (Figure 2A), which
is also involved in stacking interactions with CDR H3 Tyr100B.
Remarkably, PGT124 utilizes three different CDR loops to targetAsp325. Furthermore, a salt bridge is formed between CDR H3
Glu100I and gp120 Arg327. However, these side-chain-mediated
PGT124 interactions contrast with the backbone-mediated
recognition of the same 324GDIR327 region by PGT128, thus high-
lighting substantial differences in how antibodies from different
lineages recognize the same region in an epitope (Figure 2B).
Furthermore, Asp325 can be substituted by Asn without
affecting PGT124 interaction as HIV-1 isolates such as CNE20
and CAAN5342.A2 with 324GNIR327 can be neutralized. This
325D/NxR327 motif is 94.1% conserved across HIV-1 strains, as
calculated using 3,045 aligned gp120 sequences (Los Alamos
HIV Database). As expected, mutation of GDIR to GAIA
completely abrogated PGT124 binding to gp120 in an ITC assay
(Figures S3A and S3B). A JRCSF pseudovirus variant containing
GAIA was poorly neutralized by PGT124 compared to wild-type,
whereas the same mutations had no effect on neutralization by
PGT128 (Figure 2D). Thus, PGT124 interacts with the highly
conserved V3 base in a distinct manner from PGT128. Accord-
ingly, successful elicitation of these two types of bnAbs may
require differently designed immunogens.
Further comparison between the PGT124:gp120 core-mV3
and PGT128:ODmV3 (PDBID:3TYG) structures confirmed that
the GDIR motif is structurally similar (1.0 A˚ Ca RMSD), although
significant flexibility is observed in the overall V3 loop conforma-
tion (2.4 A˚ Ca RMSD), where the observed ends of the V3 loop
shift by 10 A˚ and 5 A˚ (Figure 2C). The PGT128 V3 conformation
is likely affected by antibody binding, as extensive interactions
are also made with the N301 glycan within the mV3.
The PGT124:core-mV3 crystal structure was also compared
with the PGT122:SOSIP.664 trimer structure (PDB ID 4NCO),
where superposition indicates that the V3 base—and the
GDIR motif in particular—adopts similar, but not identical, con-
formations (Figure S4), suggesting that binding does not sub-
stantially perturb the gp120 conformation in monomer or trimer
context.Cell 159, 69–79, September 25, 2014 ª2014 Elsevier Inc. 71
Figure 3. Interaction between PGT124 and
the N332 Glycan
(A) Interaction of the CDR loops of PGT124 in
purple with the oligomannose glycan at the N332
position in red ball-and-stick representation with
the D1, D2, and D3 arms labeled.
(B) For comparison, the interaction of the PGT128
CDR loops (light green) is shown with the N332
glycan (gray ball-and-stick representation).
(C) The N332 glycan structures bound to PGT128
or PGT124 are shown after superposition of the
gp120 protein components. Conformational dif-
ferences are highlighted by comparative distances
between equivalent mannose moieties.
(D) Schematic diagram of theMan8GlcNAc2 glycan
with the glycan moiety nomenclature.
(E) The effect on PGT124 neutralization activity of
differences in gp120 glycosylation arising from
different cell expression systems and removal of
the N332 glycan. Values are shown as IC50 in mg/ml
(see also Figures S3, S5, and S6 and Tables S2
and S3).Man8/9 Linked to Asn332 Is the Primary PGT124 Glycan
Contact in the N332 Supersite of Vulnerability
The PGT124 structure reveals the molecular basis for the highly
focused N332 glycan interaction. The antibody engages carbo-
hydrate primarily at the junction of the light (LC) and heavy
(HC) chains (Figure 3A) and makes multiple interactions to
gp120 via CDR L2, light-chain framework 3 (FR L3), and the
24-residue CDR H3 that forms an extended b hairpin (Figure 3A).
The long H3 loop penetrates the glycan shield to reach the gp120
protein surface, and its extended backbone packs along the
entire length of the N332 glycan. Additional glycan interactions
are made with a pocket formed by CDR L2, FR L3, and CDR
H3, where the C-mannose moiety forms hydrogen bonds and
van der Waals interactions (Figure 3D). Site-directed alanine
mutagenesis confirms that AsnL51 and ArgH100, which directly
contact the glycan, moderately affect PGT124 neutralization,
whereas IleL66b has a weaker effect (Figure S5). Together, these
extensive glycan contacts, in combination with interactions with
the GDIR motif, appear to be sufficient to attain high-affinity
binding, without engaging other glycans, as with PGT128 and
PGT135. Nevertheless, although PGT124 contacts the three
mannose moieties on the D1 arm, only two seem to impact
neutralization (Figure S5). Moreover, PGT124 can neutralize vi-
ruses grown in different cell lines or in the presence of glycosi-
dase inhibitors (Figure 3E), presumably because theN332 glycan
composition is not significantly impacted as it is protected from
modifying enzymes by the dense oligomannose patch on the
gp120 outer domain (Bonomelli et al., 2011).
Cocrystal structures of gp120 with a variety of N332-depen-
dent bnAbs (PGT128 [PDB ID 3TYG], PGT135 [PDB ID 4JM2],
and PGT124) allow assessment of the structure and conforma-
tional flexibility of the N332 glycan. First, superimposition of their
gp120 protein components shows that the D1, D2, and D3 arms
of the N332 glycan generally project in the same direction. How-
ever, while the PGT135- and PG128-bound N332 glycans vary
by only 8 in an arc from each other, the PGT124-bound N332
deviates by 20–25 from its corresponding orientations in the72 Cell 159, 69–79, September 25, 2014 ª2014 Elsevier Inc.PGT128 and PGT135 complexes, bending closer toward the
V3 loop (Figures 3A–3C, S6A, and S6B). Otherwise, the N332
glycan seems to have a rather rigid architecture. Superimposi-
tion only on the N332 glycan reveals remarkably good corre-
spondence of the glycan conformation with only slight deviations
(Figure S6C) as reflected in all-atom rmsds of 2.5 A˚ and 2.9 A˚ for
N332-PGT124 versus N332-PGT135 and N332-PGT124 versus
N332-PGT128 structures, respectively. Thus, the N332 glycan
has a consistent similar general orientation, but antibodies can
fix some of the apparently limited conformational heterogeneity.
Finally, PGT124 binds a different face of the glycan than PGT135,
which interacts with the N332 D2 and D3 arms rather than D1. In
contrast, PGT124 contacts the same glycan face as PGT128,
which binds the D1 and D3 arms. Consequently, this variation
in N332 glycan recognition and binding modes creates specific
footprints for each antibody.
Although derived from the same putative germline precursor,
PGT124 and PGT122 make different sets of glycan contacts.
PGT124 contacts only N332 on the JRCSF gp120 core, whereas
PGT122 contacts four different glycans on the BG505 SOSIP.664
trimer (Julien et al., 2013a). Indeed, in the absence of the N332
glycan, PGT122 requires N137 and N301 to neutralize the
BG505 virus (Julien et al., 2013a). To determine whether
PGT124 also depends on these glycans, we eliminated single
glycan sites in the V1/V2 loops and in the high-mannose patch
of Env; these changes had little to no effect on PGT124 neutral-
ization (Table S2). Consistent with the structural data, only N332
glycan removal abrogated PGT124 neutralization across a num-
ber of isolates (Sok et al., 2014). In contrast, PGT121 exhibits
isolate-specific effects in the presence or absence of N332 (Ta-
ble S2) (Sok et al., 2013), likely reflecting its ability to utilize alter-
native glycans at either N137 or N301 (Sok et al., 2014). Removal
of these glycan sites individually did not affect or even enhance
PGT121 activity, implying that each glycan interaction is rela-
tively weak. Thus, it appears that the glycans are recognized in
combination with the protein component via a cooperative inter-
action to achieve a high-affinity interaction. Although PGT124
Figure 4. Epitope Core of the PGT121 Germ-
line Lineage
(A) Cartoon representation of the interaction be-
tween mV3-gp120 core and the PGT124 variable
region (left) and close-up views of the PGT124
epitope core with the 324GDIR327 motif at the V3
base in blue spheres and the N332 glycan as pale
green ball and stick (middle and right). The PGT124
residues that contact the N332 glycan and the V3
proteinmotif are represented in red and orange as a
ball and stick, respectively, and covered with its
molecular surface.
(B) Sequence alignment of heavy and light chains of
PGT121–124 Abs and germline precursors (asterisk
indicates that the germline CDR L3 and CDR H3
sequences are not used for alignment because of
ambiguity associated with D gene assignment).
Red and orange boxes indicate that residues that
contact the N332 glycan and the GDIR motif,
respectively, on the epitope core of PGT124 are
also largely conserved in PGT121–123 and,
importantly, in the germline sequence (see also
Figure S1).and PGT121/PGT122 derive from the same germline genes and
have high structural homology, they have diverged significantly in
how they interact with their epitopes centered on the N332
glycan. Nevertheless, the entire constellation of glycans likely
dictates the approach angle of these antibodies to the Env trimer
where either several (PGT122) glycans or one (PGT124) glycan
are contacted and others are avoided.
We previously reported that removal of the N332 glycan
abrogates PGT124 neutralization for the overwhelming majority
of isolates (Sok et al., 2014). To determine how PGT124 neutral-
izes HIV in the absence of N332, we investigated a small set of
representative isolates (Table S3). Neighboring glycan sites
were removed in combination with N332 by alanine muta-
genesis, and the double mutants were tested to see whether
PGT124 was dependent on them for neutralization. Loss of
neutralization was found for removal of N295, N301, N339, and
N392 glycan sites in combination with N332 removal, but little
to no effect was seen with single mutations (Table S3). Accord-
ingly, for a small subset of viruses, PGT124 is capable of utilizing
nearby glycans when N332 is not present (Table S3).
PGT124 Binding Does Not Appear to Be Dependent
on Other Surrounding Glycans on the HIV-1 Trimer
PGT124 primarily contacts N332, whereas PGT122 also con-
tacts N137, N156, and N301 (Figure 1) (Julien et al., 2013a).
Therefore, we analyzed sequences in this family in the context
of known structures to assess the evolution of their binding sites
during antibodymaturation. Residues in common in PGT122 and
PGT124 CDRs mediate contacts to N332 and GDIR (Figure 4).
Indeed, almost all of these contact residues are also present in
the germline (GL) and are retained in various intermediates (3H,
32H, and 9H for the heavy chain and 3L for the light chain), as
well as in the affinity-matured antibodies from different branches
of the phylogenetic tree (PGT121–124). Thus, N332 glycan and
GDIR recognition appears to be the key event in initiating the
antibody response.Comparison of HIV neutralization by inferred intermediates
and affinity-matured antibodies against various glycan mutants
reveals considerable complexity in glycan epitope recognition.
We therefore focused on the four glycan sites (N137, N156,
N301, and N332) that mediate binding of PGT122 to the
BG505 isolate. We tested neutralization of antibody 3H+3L,
the least-mutated inferred intermediate for this lineage, as well
as 32H+3L that is an inferred intermediate of PGT124, and
9H+3L as an inferred intermediate of PGT121–123. First, we
observed loss of neutralization for 3H+3L upon removal of indi-
vidual glycan sites at N301 and N332, as previously reported
(Sok et al., 2013), implying use of both glycan sites early in
this lineage (Table S4). Neutralization was reduced after N301
removal for 32H+3L and 9H+3L with complete loss after N332
removal, suggesting a somewhat reduced dependence on
N301 during affinity maturation relative to N332. A similar
pattern was observed for other isolates (Sok et al., 2013). Strik-
ingly, N137 removal resulted in enhanced neutralization for both
inferred intermediate antibodies and for the affinity-matured an-
tibodies (Table S4), suggesting that the N137 glycan plays a
largely obstructive role. However, in the absence of the N332
glycan, it appears that the N137 glycan can play a positive bind-
ing role. If N332 and N137 are both eliminated, antibodies from
the PGT121 family fail to neutralize virus. The overall conclusion
is that the N332 glycan is preferentially used by all antibodies of
the PGT121 lineage but that the N137 glycan can be utilized by
PGT121–123 if N332 is absent (Table S5). Moreover, this effect
is also observed to a lesser degree for N301 and N156 glycans
that do not generally contribute to binding in the presence of
N332 but become important for PGT121–123 in the absence
of N332 (Table S4). In contrast, for the PGT124 branch, the
N332 glycan appears to be sufficient for neutralization and con-
tact with N137 is avoided (Tables S4 and S5). Thus, markedly
different epitope recognition is observed for antibodies derived
from the same germline lineage. With regard to the N301 glycan,
PGT124 CDR H2 is shifted away from its equivalent position inCell 159, 69–79, September 25, 2014 ª2014 Elsevier Inc. 73
Figure 5. PGT122 Contacts Glycans at N137 and N301, but PGT124
Accommodates These Glycans without Forming Contacts
(A) The PGT122 epitope is composed of V1 and V3 regions from gp120, as well
as four glycans at N137, N156, N301, and N332. The CDR loops and FR3 are
shown in cartoon representation (in gray) (PDB ID: 4NCO).
(B) Superposition of PGT124 (in purple) on the PGT122 epitope.
(C) Although PGT124 seems capable of accommodating a glycan in the open
face formed by H2 and H3, those loops appear to be shifted toward the center
of the epitope when compared to the PGT122 paratope, thereby avoiding
contacts with the N137 glycan.
(D) However, PGT124 is predicted to clash with the 301 glycan and presum-
ably pushes this glycan away to access the protein surface below.PGT122 (Figure 5C) and toward N301 glycan (Figure 5D). In fact,
PGT124 would clash with N301 if it were to maintain the same
orientation it adopts in the PGT122 complex. Thus, PGT124
appears to avoid this glycan consistent with apparent cleavage
by EndoH in the presence of PGT124 and no visible electron
density.
As previously observed, glycan arrays indicated that PGT121
binds biantennary complex glycans containing terminal sialic
acid moieties with a-6 linkages (Julien et al., 2013c; Mouquet
et al., 2012), but not high-mannose glycans (Figures 6A–6C).
PGT128 and 2G12 only bind high-mannose glycans on glycan
arrays (Calarese et al., 2003; Pejchal et al., 2011). In contrast,
PGT124 does not bind any glycans on these arrays (Figures
6A–6C). The lack of complex glycan binding is consistent with
the structural evidence that PGT124 does not interact with V1/
V2 glycans, which are likely complex. Indeed, similar data were
reported for 10-1074, a closely related somatic variant of
PGT124 (Figure S1B) (Mouquet et al., 2012). However, lack of
detectable high-mannose binding to PGT124 on the arrays is
more puzzling but is consistent with weak interaction with the
N332 glycan that requires cooperative interaction with the
GDIR motif to attain high-affinity binding. For WEAU, one of
the few HIV-1 strains in which N332A mutation does not abro-
gate PGT124 neutralization, virus produced in the presence of
kifunensine, which results in only Man8-9GlcNAc2 glycoforms,
is more sensitive to PGT124 neutralization than wild-type virus,
suggesting that complex glycans are not required for PGT12474 Cell 159, 69–79, September 25, 2014 ª2014 Elsevier Inc.neutralization even in the absence of N332, in contrast to
PGT121 (Figure S7).
PGT121–123 allosterically inhibit CD4 binding to gp120 by in-
teractingwith the V1/V2 loop (Julien et al., 2013c). To test whether
this mechanism also applies to PGT124, we performed sequen-
tial ITC binding experiments in which CD4 was titrated into a so-
lution containing full-length gp120 precomplexedwith PGT124 or
vice versa. We found no difference in PGT124 or CD4 binding
whether or not the other was precomplexed with full-length
gp120 (PGT124: Kd of 38 nM versus 34 nM precomplexed with
CD4; CD4: Kd of 55 nM versus 50 nM precomplexed with
PGT124). Thus, PGT124 does not inhibit gp120-CD4 binding,
either allosterically or otherwise, which further highlights differ-
ences in epitope recognition compared to PGT121 (Figure S3E).
DISCUSSION
Following HIV-1 infection, a proportion of individuals develops
potent broadly neutralizing antibody responses over time. Typi-
cally, sets of monoclonal antibodies can be isolated that consist
of somatic variants arising from a single germline precursor, but
individual variants can differ considerably in sequence, neutraliza-
tion profiles, and breadth. Investigation of these somatic variants
can aid in understanding what to expect from a vaccine-induced
polyclonal antibody response to a given epitope and highlight fea-
tures that might be gainfully incorporated into a vaccine immu-
nogen and in vaccination strategies designed to elicit antibodies
to that epitope.
To this end, we performed a structural study ofmembers of the
highly potent PGT124 family of bnAbs. PGT121, for example,
protects against virus challenge at exceptionally low serum titers
in macaque models (Moldt et al., 2012). Previous work also
noted differences in glycan site recognition between somatic
variants (Sok et al., 2014), and phylogenetic studies reported
divergence in affinity maturation between PGT121–123 and 10-
1074/PGT124 (Mouquet et al., 2012; Sok et al., 2013). We there-
fore investigated these phenotypic differences by comparing
epitope recognition between somatic variants PGT122 and
PGT124 in atomic detail.
The overall binding site architectures of the PGT124/10-1074,
PGT121–123, and germline precursor antibodies are strikingly
similar; all contain a closed face (Julien et al., 2013c; Mouquet
et al., 2012) on one side of the paratope for binding the N332
glycan and similarly oriented long CDR loops that reach through
to the protein surface below (Figure S1B). All antibodies also
have an equivalent open face with a U-shaped depression; for
PGT122, this face contacts surrounding glycans, whereas for
PGT124, it enables avoidance of neighboring glycans. These ob-
servations suggest that, from the initial recombination event, the
overall shape of the germline precursor is compatible with pene-
tration of the glycan shield on the Env trimer in the region of N332
(Figure S1B). Indeed, the germline precursor already contains 8
of the 11 residues that are used by PGT124 to recognize the
N332 glycan (5 residues) and the GDIR peptide sequence (6 res-
idues) (Figure 4). A three amino acid insertion in FR L3, which
occurred early in the maturation process, makes key contacts
to the N332 glycan, highlighting its importance for the binding
and neutralization by this antibody family (Sok et al., 2013).
Figure 6. Evolution of Recognition of Com-
plex Glycans by the PGT121 Family
(A) Key residues on PGT121 (Kabat numbering)
that contact the complex glycan attached at N137
of gp120 V1 are represented in red as a stick and
ball and are covered with its molecular surface on
the ribbon representation of the antibody variable
regions (left). Residues at equivalent positions on
PGT124 are highlighted in orange (right).
(B) Sequence alignment for heavy-chain variable
region for the germline precursor (GL) (asterisk in-
dicates that the germline CDR H3 sequence is not
used for the alignment because of ambiguity
associated with D gene assignment), intermediate
precursors (3H, 32H, and 9H), and mature anti-
bodies of the PGT121 family (PGT121–124). Red
boxes indicate residues involved in N137 glycan
binding by PGT121, whereas orange boxes in-
dicate the residues at equivalent positions on
PGT124.
(C) Glycan arrays illustrate that PGT124, in contrast
to PGT121, PGT128, or 2G12, does not bind either
complex or high-mannose glycans with any
demonstrable affinity (see also Figures S1, S3, and
S7). Error bars, SD; n = 6; RFU, relative fluores-
cence units.However, the structural analyses, as well as neutralization and
binding assays, revealed a remarkable divergence in glycan
epitope recognition by this antibody lineage that could have
been driven by changes in the glycan sites over the course of
chronic infection, although this hypothesis cannot be tested
directly as longitudinal samples are not available. However,
enhanced neutralization by all members of this lineage in the
absence of the N137 glycan suggests that the initial encounter
with this glycan was unfavorable, if it was present, but likely
contributed to selecting the overall antibody shape required to
bind the N332 glycan, penetrate through the glycan shield to ac-
cess the V3 base, and avoid unfavorable contacts with other
neighboring glycans. Following this initial event, antibody ma-
turation appears to have proceeded along two different paths.
Via the PGT124 route, affinity maturation appears to have
focused on recognition on the V3 base and the N332 glycan.
For PGT121–123, affinity maturation appears to have expanded
the recognition to up to four glycans, including N137, depending
upon isolate context, which likely could counter potential virus
escape through deletion of the N332 glycan (Figure 7). Even
though the PGT124 epitope is substantially smaller than
PGT121–123, PGT124’s potency and breadth match the other
antibodies (Sok et al., 2014). One possible explanation is that in-
teractions with the protein component substitute for binding to
multiple glycans. Accordingly, the GDIRmotif is just as important
as the N332 glycan for binding and neutralization for most iso-
lates (Figures 2D, 3E, S3B, and S3C). Thus, the single glycan
at N332 is necessary but not sufficient because the GDIR motif
is also required for PGT124 binding and neutralization.
Our observations also highlight the inherent flexibility in how
glycans can serve as binding sites for antibodies as well as for
other proteins. Furthermore, N137 glycan deletion in the pres-ence of the N332 glycan enhances neutralization of BG505, indi-
cating that this glycan can restrict antibody recognition. In
contrast, deletion of both N137 and N332 totally abrogates
PGT121–123 neutralization against the BG505 strain (Figure 7
and Table S4). Thus, the same glycan can participate in or shield
a neutralizing epitope. For example, deletion of the N156 glycan
has no effect on neutralization by any PGT121 lineage antibody
except when N332 is absent, where some dependency is now
observed (PGT122 and PGT123) (Table S4). In contrast, N332
makes productive contacts with all antibodies, confirming its
role in the epitope core. The N301 glycan is important for neutral-
izing activities of the 3H precursor and, to a lesser extent, 9H and
32H precursors (Table S4). In contrast, in the absence of N332,
PGT121 and particularly PGT122 show some dependency on
N301, whereas deletion of both glycans completely abrogates
binding of PGT123 (Table S4). In summary, several glycans
may be involved in initiating an early PGT121 family response,
but different maturation pathways result in divergent glycan
recognition profiles. This complexity in glycan recognition may
be generalized to other antibodies such as PG9 and PG16 (Pan-
cera et al., 2013; Walker et al., 2009), which both recognize N156
and N160 in V1/V2, but PG9 has evolved a preference for N160,
whereas PG16 favors N156 (McLellan et al., 2011; Pancera et al.,
2013).
These results also have implications for protein-glycan recog-
nition and vaccine design. Broader recognition of glycoproteins
or glycopeptides can be achieved by focusing recognition on the
conserved core of otherwise variable glycans. Second, because
of such conserved features, neighboring glycans may be able to
substitute for some variation in glycan location. Third, affinity can
be enhanced by binding to multiple glycans even within a single
binding site and also by latching on to the conserved regions ofCell 159, 69–79, September 25, 2014 ª2014 Elsevier Inc. 75
Figure 7. Summary of the Contributions of
the N137, N156, N301, and N332 Glycans to
Recognition of the BG505 Isolate by Anti-
bodies of the PGT121 Lineage
Early precursors are highly dependent on the N301
and N332 glycans for neutralization and are nega-
tively impacted by the presence of the N137 glycan
(asterisk indicates that N137 glycan can play a
double role in glycan recognition—first it can inhibit
antibody binding by shielding the epitope, here
represented in blue, and second, although it can
still inhibit antibody binding to some extent, the
N137 glycan can also be used by PGT121–123 to
neutralize BG505 in the absence of N332, here
represented in blue/red). Affinity maturation ap-
pears to create two distinct lineages that evolve
separate dependencies on glycans that surround
N332. N332 is the only critical glycan in the PGT124
epitope, whereas the N137 glycan contributes
negatively to recognition by this antibody. Fold
changes in neutralization IC50 for single and double
glycan mutants (Table S4) were used to determine
whether a glycan positively contributes to the
epitope (decrease in neutralization IC50 upon
removal) or contributes to shielding of the epitope
(increase in neutralization IC50 upon removal). A
relative scale for both positive and negative glycan
contributions to the epitope was determined based
on the extent of the change in neutralization IC50.
Interestingly, for PGT121–123, the N137 glycan
contributes to shielding in the presence of N332
but is a critical part of the epitope in the absence of
N332 (see also Table S4 and S5).the protein, albeit even very short segments. For vaccine design,
further considerations must be taken into account. For the
PGT121 family, immunogens would first be designed to select
for germline antibodies with relatively long CDR H3 lengths (24
amino acids) that could insert between the glycans and reach
the underlying protein surface below. An appropriate antibody
shape would be required for intimate binding of the N332 glycan
(closed face in the PGT121 family), and another cavity (open
face) to contact (PGT121–123) or avoid (PGT124) surrounding
glycans. To facilitate initial engagement, an immunogen without
the N137 glycan may enhance epitope recognition as illustrated
for engagement of germline antibodies to the CD4 binding site by
removal of a blocking glycan (Jardine et al., 2013). It is not yet
clear whether removal of a blocking glycan would compromise
selection of an appropriately shaped antibody. Following this
initial selection event, modified immunogens would be used to
drive clonal diversity of the selected antibody germline family
that could include adding back or altering glycans to emulate
events that likely occurs during virus evolution under immune
pressure. To achieve a productive angle of approach of the anti-
body in the context of the Env trimer, the immunogenwould likely
require a native glycan shield or native-like Env structure to
encourage accommodation of potentially obstructive neigh-
boring glycans and drive somatic mutations to productively uti-
lize neighboring glycans. Thus, these results provide insights
into protein recognition of glycosylated proteins and demon-
strate the remarkable ability of the human immune system to
find and evolve multiple solutions for high-affinity antibody bind-76 Cell 159, 69–79, September 25, 2014 ª2014 Elsevier Inc.ing of complex epitopes so as to neutralize highly variable and
highly glycosylated viruses, such as HIV.
EXPERIMENTAL PROCEDURES
Expression and Purification of Proteins
CD4 was expressed in E. coli BL-21 DE3* cells in LB media and purified by
affinity chromatography followed by size exclusion chromatography (SEC).
PGT124 Fab was produced in FreeStyle 293F cells (Invitrogen) and purified
by affinity chromatography followed by cation exchange chromatography
and SEC. JRCSF gp120 core was produced in FreeStyle 293S. Protein was
purified using a GN Lectin column, followed by SEC. BG505 SOSIP.664 trimer
was expressed in FreeStyle 293F or 293S cells and purified using a 2G12-
coupled affinity matrix followed by SEC (Extended Experimental Procedures).
Formation of Protein Complexes, Crystallization,
and Data Collection
Complexes were formed by combining gp120:ligands in a 1:1.2 molar ratio,
followed by deglycosylation with Endoglycosidase H before being purified
by SEC. Crystals of PGT124-gp120coremV3-CD4 ternary complex were
obtained from 2.4 M (NH4)2SO4, 0.1 M Tris (pH 8.0), and 13% glycerol that dif-
fracted to 3.3A˚ resolution (Table S1). Unliganded PGT124 Fab crystals ap-
peared from 20% (w/v) PEG 4000, 0.2 M MgCl2, and 0.1 M Tris-HCl (pH 8.5)
and diffracted to 2.5 A˚ (Extended Experimental Procedures and Table S1).
Structure Determination and Refinement
The unliganded PGT124 structure was solved bymolecular replacement using
Phaser with the PGT122 Fab structure (PDB 4JY5) as the initial model in which
the CDR loops had been deleted. For the ternary complex, multiple compo-
nents were used for phasing: CD4-gp120 (PDB ID:4JM2) and the high-resolu-
tion unliganded PGT124 Fab. Model building and refinement were carried out
using Coot (Emsley and Cowtan, 2004) and Phenix (Adams et al., 2010),
respectively. Table S6 shows the components that were included in the final
model. Rcryst and Rfree for the unliganded structure are 23.5% and 26.7%
and 21.0% and 26.3% for the complex (Table S1). Buried molecular surface
areas were analyzed with the Molecular Surface Package (Connolly, 1993) us-
ing a 1.7 A˚ probe radius. The Fab residues were numbered according to Kabat
(Martin, 1996), and gp120 is numbered following the Hxbc scheme (Ratner
et al., 1987).
Isothermal Titration Calorimetry
ITC binding experiments were performed using a MicroCal Auto-iTC200 in-
strument (GE). All proteins were extensively dialyzed against a buffer contain-
ing 20 mM Tris and 150 mM NaCl (pH 7.4), and protein concentrations were
adjusted and confirmed using calculated extinction coefficients and absor-
bance at 280 nm. In the syringe, ligand was either PGT124 Fab or sCD4 at con-
centrations ranging between 60 and 125 mM. The gp120 monomer was in the
cell at concentrations ranging between 3.5 and10 mM. Two-protein binding ex-
periments were performed as follows: cell at 25C, 16 injections of 2.5 ml each,
injection interval of 180 s, injection duration of 5 s, and reference power of
5 mcals. To perform sequential binding experiments, the mixed sample from
the first titration was left in the cell, and the concentration of the HIV-1 compo-
nent was recalculated based on the dilution from the first experiment (88%of
the initial concentration). Subsequently, either PGT124 Fab or sCD4 was
added in a second titration. To calculate the affinity constants (KD), the molar
reaction enthalpy (DH) and the stoichiometry of binding (N), Origin 7.0 software
was used by fitting the integrated titration peaks using a single-site binding
model.
Antibody and Envelope Substitutions
Substitutions in the PGT124 paratope, the HIV-1 Env glycoprotein, and
the JRCSFmV3 construct were introduced using QuikChange site-directed
mutagenesis (Stratagene). Substitutions were verified by DNA sequencing
(Retrogen).
Neutralization Assays
Neutralization activity of antibodies against pseudovirus in TZM-bl cells was
determined as described previously (Li et al., 2005).
Electron Microscopy
PGT124 Fab in complex with BG505 SOSIP.664 gp140 produced in HEK293S
cells were analyzed by negative stain EM. A 3 ml aliquot of 10 mg/ml of the com-
plex was applied for 15 s onto a glow-discharged, carbon-coated 400 Cu
mesh grid and stained with 2% uranyl formate for 20 s. Grids were imaged us-
ing a FEI Tecnai T12 electron microscope operating at 120 kV using 52,0003
magnification and electron dose of 25 e/A˚2, resulting in a pixel size of 2.05 A˚ at
the specimen plane. Images were acquired with a Tietz 4k3 4kCCD camera in
5 tilt increments from 0 to 55 at a defocus of 1,000 nm using LEGINON (Su-
loway et al., 2005).
Image Processing
Particles were picked automatically by using DoGPicker and put into a particle
stack using the Appion software package (Lander et al., 2009; Voss et al.,
2009). Initial reference-free 2D class averages were calculated using unbinned
particles via the Xmipp Clustering 2D Alignment and sorted into 400 classes
(Sorzano et al., 2010). Particles corresponding to the complexes were selected
into a substack, and another round of reference-free alignment was carried out
using Xmipp Clustering 2D alignment and IMAGIC software (van Heel et al.,
1996). To generate an ab initio 3D starting model, a template stack of 120 im-
ages of 2D class averages was used with imposing C3 symmetry. This starting
model was refined against 12,245 raw particles for 30 cycles using EMAN
(Ludtke et al., 1999). The resolution of the final reconstruction was calculated
to be 17.8 A˚ using an FSC cutoff of 0.5 (Figure S2).
Glycan Array Production
Glycan arrays were custom printed on a MicroGridII (Digilab) contact microar-
ray robot equipped with StealthSMP4B microarray pins (Telechem) as previ-
ously described. Briefly, samples of each glycan were diluted to 100 mM in
150 NaPO4 buffer (pH 8.4). Aliquots of 10 mL were loaded in 384-well platesand imprinted onto NHS-activated glass slides (SlideH, Schott/Nexterion)
with 7 arrays, each containing 6 replicates of each sample at both concentra-
tions. Printed slides were humidified postprint for 1 hr and desiccated over-
night. Remaining NHS-ester residues were quenched by immersing slides in
50 mM ethanolamine in 50 mM borate buffer (pH 9.2) for 1 hr. Blocked slides
were washed with water, spun dry, and stored at room temperature until use.
Glycan Array Screening and Analyses
Antibodies were diluted to 30 mg/ml + 15 mg/ml anti-human-IgG-RPE (Jackso-
nImmuno) in PBS + 0.05% Tween-20. The preparedmixture was incubated for
30 min on ice and incubated on the array surface in a humidified chamber for
1 hr. Slides were subsequently washed by successive rinses with PBS-T, PBS,
and deionized H2O. Washed arrays were dried by centrifugation and immedi-
ately scanned for FITC and R-PE signal on a Perkin-Elmer ProScanArray Ex-
press confocal microarray scanner. Fluorescent signal intensity wasmeasured
using Imagene (Biodiscovery), and mean intensity minus mean background
was calculated and graphed using MS Excel.
ACCESSION NUMBERS
Coordinates and structure factors for Fab PGT124 and its complex with gp120
and CD4 are deposited with the PDB under accession codes 4R26 and 4R2G,
respectively. The Fab PGT124:SOSIP.664 trimer EM reconstruction is depos-
ited in the EMDB under accession code EMD-2753. The nucleotide sequences
for the antibodies 3L, 3H, 32H, 9H, PGT124HC, and PGT124LC are deposited
with the GenBank under the accession numbers KM507475, KM507476,
KM507477, KM507478, KM507479, and KM507480, respectively.
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